ArticleInternational journal of chronic obstructive pulmonary disease2025
Paradigm Shift in the Treatment of Chronic Obstructive Pulmonary Disease Improves Patient Outcomes.
Article in International journal of chronic obstructive pulmonary disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Impact of umeclidinium/vilanterol dual bronchodilator therapy on pulmonary function and inflammatory responses in stable COPD patients.Scientific reports · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Purpose: This study evaluates the real-world impact of LAMA+LABA combination therapy on COPD outcomes, bridging the gap between experimental data and clinical practice. It aims to assess whether the paradigm shift in the treatment of chronic obstructive pulmonary disease has improved patient outcomes, particularly in terms of acute exacerbations, hospitalizations, and mortality, while providing insights to guide clinical and policy decisions. Patients and Methods: This retrospective study analyzes cohorts derived from outpatient and inpatient medical records from Taiwan's National Health Insurance Research Database. It includes individuals diagnosed with COPD in two periods: 2012-2014 and 2016-2018. Results: The paradigm shift in COPD treatment has led to a significant transition in medication selection, moving away from single-agent or supplementary inhaled corticosteroid (ICS) regimens (from 99.61% to 20.99%) towards the use of dual bronchodilators or triple therapy (from 0.38% to 79.02%). The analysis between long-acting muscarinic antagonists (LAMAs) and long-acting beta-agonists (LABAs) revealed no statistically significant differences in emergency department visits and hospitalizations. However, LABAs were associated with a notable reduction in all-cause mortality compared to LAMAs (aHR 0.674-0.765). Additionally, the widespread adoption of dual bronchodilator therapy and the implementation of precise guidelines for ICS use have led to significant reductions in emergency department visits (aHR 0.557-0.735), decreased hospitalizations (aHR 0.610-0.725), and improved mortality outcomes (aHR 0.226-0.294) among COPD patients. Conclusion: The paradigm shift in treatment approaches has led to substantial improvements in patient outcomes for COPD, regardless of the treatment regimen employed. This development marks a significant advancement in enhancing both the efficacy and precision of COPD management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.